KR102675860B1 - 구조적 보완에 의한 바이오발광성의 활성화 - Google Patents

구조적 보완에 의한 바이오발광성의 활성화 Download PDF

Info

Publication number
KR102675860B1
KR102675860B1 KR1020217008951A KR20217008951A KR102675860B1 KR 102675860 B1 KR102675860 B1 KR 102675860B1 KR 1020217008951 A KR1020217008951 A KR 1020217008951A KR 20217008951 A KR20217008951 A KR 20217008951A KR 102675860 B1 KR102675860 B1 KR 102675860B1
Authority
KR
South Korea
Prior art keywords
luminescent
luminescence
peptide
nlpoly
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217008951A
Other languages
English (en)
Korean (ko)
Other versions
KR20210036422A (ko
Inventor
앤드류 에스. 딕슨
랜스 엔셀
메리 홀
키이스 우드
모니카 우드
마리 슈윈
브록 에프. 빈코브스키
히참 제그조우티
니드히 나스
수브한잔 몬달
사이드 고우엘리
폰초 마이젠하이머
토마스 커클랜드
제임스 운치
딜리프 케이. 풀루쿠나트
매튜 로버스
멜라니 다트
토마스 마흐라이트
Original Assignee
프로메가 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메가 코포레이션 filed Critical 프로메가 코포레이션
Priority to KR1020237017712A priority Critical patent/KR20230079494A/ko
Publication of KR20210036422A publication Critical patent/KR20210036422A/ko
Application granted granted Critical
Publication of KR102675860B1 publication Critical patent/KR102675860B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Finance (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Strategic Management (AREA)
  • Signal Processing (AREA)
  • General Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Veterinary Medicine (AREA)
KR1020217008951A 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화 Active KR102675860B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237017712A KR20230079494A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
US61/791,549 2013-03-15
KR1020157024687A KR20150129721A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화
PCT/US2014/026354 WO2014151736A1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024687A Division KR20150129721A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017712A Division KR20230079494A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화

Publications (2)

Publication Number Publication Date
KR20210036422A KR20210036422A (ko) 2021-04-02
KR102675860B1 true KR102675860B1 (ko) 2024-06-20

Family

ID=51581027

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217008951A Active KR102675860B1 (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화
KR1020237017712A Ceased KR20230079494A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화
KR1020157024687A Ceased KR20150129721A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237017712A Ceased KR20230079494A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화
KR1020157024687A Ceased KR20150129721A (ko) 2013-03-15 2014-03-13 구조적 보완에 의한 바이오발광성의 활성화

Country Status (15)

Country Link
US (11) US9797889B2 (cg-RX-API-DMAC7.html)
EP (4) EP3783011B1 (cg-RX-API-DMAC7.html)
JP (4) JP6654557B2 (cg-RX-API-DMAC7.html)
KR (3) KR102675860B1 (cg-RX-API-DMAC7.html)
CN (2) CN105143249A (cg-RX-API-DMAC7.html)
AU (3) AU2014236949C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023394B8 (cg-RX-API-DMAC7.html)
CA (3) CA3249512A1 (cg-RX-API-DMAC7.html)
DK (2) DK3783011T5 (cg-RX-API-DMAC7.html)
ES (2) ES2929362T3 (cg-RX-API-DMAC7.html)
IL (3) IL286816B (cg-RX-API-DMAC7.html)
PL (2) PL2970412T3 (cg-RX-API-DMAC7.html)
PT (2) PT3783011T (cg-RX-API-DMAC7.html)
SG (2) SG11201507306VA (cg-RX-API-DMAC7.html)
WO (1) WO2014151736A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236949C1 (en) 2013-03-15 2018-11-29 Promega Corporation Activation of bioluminescence by structural complementation
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags
EP4455668A3 (en) 2015-02-05 2025-02-19 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
AU2017345560C1 (en) 2016-10-20 2025-04-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3395803A1 (en) 2017-04-28 2018-10-31 Institut Pasteur Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins
CA3022981C (en) * 2017-11-01 2025-05-06 Queen's University At Kingston HIPPO BIOLUMINOUS TRAIL BIOSENSOR
WO2019164402A1 (en) * 2018-02-26 2019-08-29 Technische Universiteit Eindhoven Bioluminescent biosensor for detecting and quantifying biomolecules
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
EP3807419A4 (en) * 2018-06-12 2022-09-07 Promega Corporation MULTIPLE LUCIFERASE
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
IL318819A (en) 2018-10-03 2025-04-01 Promega Corp Compounds and methods for stabilizing cholinetyrazine and its derivatives
WO2020113036A2 (en) 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
EP3891503A2 (en) 2018-12-04 2021-10-13 Promega Corporation Broad spectrum gpcr binding agents
US11913944B2 (en) 2019-03-20 2024-02-27 Promega Corporation Photoaffinity probes
AU2020272037B2 (en) * 2019-04-10 2025-11-27 Promega Corporation Compositions and methods for analyte detection using bioluminescence
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
CN114450326B (zh) 2019-06-24 2025-02-11 普罗美加公司 用于将生物分子递送到细胞中的改性聚胺聚合物
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
US20230031446A1 (en) * 2019-11-22 2023-02-02 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
IL293204B1 (en) 2019-11-27 2026-08-01 Promega Corp Multipartite luciferase peptides and polypeptides
WO2021119149A1 (en) 2019-12-10 2021-06-17 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
EP4127148A1 (en) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reporter system for radionuclide imaging
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
JP7677997B2 (ja) 2020-05-22 2025-05-15 プロメガ コーポレイション キナーゼターゲットエンゲージメントの増強
WO2022047186A1 (en) 2020-08-28 2022-03-03 Promega Corporation Target engagement assay for ras proteins
EP4337646A4 (en) 2021-05-13 2025-05-21 Promega Corporation BIOLUMINESCENT DETECTION OF DNA SYNTHESIS
US20240252689A1 (en) * 2021-05-18 2024-08-01 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
US20240132859A1 (en) 2022-05-04 2024-04-25 Promega Corporation Modified dehalogenase with extended surface loop regions
WO2023215514A2 (en) 2022-05-04 2023-11-09 Promega Corporation Bioluminescence-triggered photocatalytic labeling
JP2025516354A (ja) 2022-05-04 2025-05-27 プロメガ コーポレイション スプリット修飾デハロゲナーゼバリアント
EP4519290A1 (en) 2022-05-04 2025-03-12 Promega Corporation Circularly permuted dehalogenase variants
WO2024151471A1 (en) 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
EP4700040A1 (en) * 2023-04-21 2026-02-25 Shenzhen Loggene Life Science & Technology Co., Ltd. Peptide and luminescent complex containing same
CN121794397A (zh) * 2023-05-04 2026-04-03 普洛麦格公司 用于双模态标记的基于互补性的标签和报告基因
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2026008850A1 (en) 2024-07-04 2026-01-08 Insempra Gmbh Linear nucleic acid templates for high-efficient cell-free protein expression
WO2026008852A2 (en) 2024-07-04 2026-01-08 Insempra Gmbh Optimized media for highly efficient cell-free protein expression systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170069A1 (en) 2007-11-01 2009-07-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell free methods for detecting protein-ligand binding
US20120117667A1 (en) 2010-11-02 2012-05-10 Klaubert Dieter H Novel coelenterazine substrates and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
KR950703582A (ko) 1992-10-14 1995-09-20 조이스 이. 마임스 킬레이트화 중합체(chelating polymers)
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
EP1156103B1 (en) * 2000-04-26 2010-08-11 Chisso Corporation Oplophorus luciferase
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
US20040115814A1 (en) * 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
EP1931787A4 (en) 2005-09-30 2010-10-20 Univ Montana State SYSTEM FOR DETECTING PROTEIN-PROTEIN INTERACTIONS
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
US20100272675A1 (en) * 2007-11-15 2010-10-28 Endocyte, Inc. Method of administering conjugates
GB2479847B (en) 2009-02-09 2014-02-19 Jnc Corp Coelenterazine analogs and manufacturing method thereof
WO2010119721A1 (ja) 2009-04-17 2010-10-21 独立行政法人産業技術総合研究所 超高輝度で安定な人工生物発光酵素
ES2795287T3 (es) 2009-05-01 2020-11-23 Promega Corp Luciferasas de Oplophorus sintéticas con mayor emisión de luz
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US10024862B2 (en) * 2012-12-12 2018-07-17 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
AU2014236949C1 (en) 2013-03-15 2018-11-29 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170069A1 (en) 2007-11-01 2009-07-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell free methods for detecting protein-ligand binding
US20120117667A1 (en) 2010-11-02 2012-05-10 Klaubert Dieter H Novel coelenterazine substrates and methods of use
US20120174242A1 (en) 2010-11-02 2012-07-05 Brock Binkowski Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use

Also Published As

Publication number Publication date
CA2906063A1 (en) 2014-09-25
US20200292534A1 (en) 2020-09-17
AU2020213288A1 (en) 2020-08-27
IL273989B (en) 2021-10-31
JP2024167207A (ja) 2024-12-03
AU2014236949C1 (en) 2018-11-29
CA3249512A1 (en) 2026-03-02
IL286816B (en) 2022-09-01
ES2926463T3 (es) 2022-10-26
JP7532562B2 (ja) 2024-08-13
JP7843318B2 (ja) 2026-04-09
JP6654557B2 (ja) 2020-02-26
US20180196038A1 (en) 2018-07-12
WO2014151736A1 (en) 2014-09-25
US10107800B2 (en) 2018-10-23
SG11201507306VA (en) 2015-10-29
US20180095074A1 (en) 2018-04-05
EP4169935A1 (en) 2023-04-26
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
US9869670B2 (en) 2018-01-16
EP2970412B1 (en) 2022-08-10
US12367513B2 (en) 2025-07-22
IL273989A (en) 2020-05-31
US20140363375A1 (en) 2014-12-11
US20250022022A1 (en) 2025-01-16
CN117024548A (zh) 2023-11-10
US20230342826A1 (en) 2023-10-26
US20180313825A1 (en) 2018-11-01
BR112015023394A2 (pt) 2017-11-28
ES2929362T3 (es) 2022-11-28
PL3783011T3 (pl) 2022-11-21
US10184936B2 (en) 2019-01-22
US10648971B2 (en) 2020-05-12
US20140348747A1 (en) 2014-11-27
US11493504B2 (en) 2022-11-08
US20180306782A1 (en) 2018-10-25
AU2018256548A1 (en) 2018-11-22
DK2970412T3 (da) 2022-08-29
JP7280842B2 (ja) 2023-05-24
AU2018256548B2 (en) 2020-05-14
CA3254603A1 (en) 2026-02-19
PT2970412T (pt) 2022-09-13
KR20230079494A (ko) 2023-06-07
PL2970412T3 (pl) 2022-11-14
JP2016519065A (ja) 2016-06-30
BR112015023394B8 (pt) 2023-09-26
JP2023055734A (ja) 2023-04-18
IL240985A0 (en) 2015-11-30
EP3783011B1 (en) 2022-09-21
EP4177261A1 (en) 2023-05-10
CA2906063C (en) 2025-10-07
US12366572B2 (en) 2025-07-22
EP2970412A4 (en) 2016-07-27
EP2970412A1 (en) 2016-01-20
KR20150129721A (ko) 2015-11-20
DK3783011T5 (da) 2024-08-19
US20160282340A1 (en) 2016-09-29
DK3783011T3 (da) 2022-10-17
US20250045806A1 (en) 2025-02-06
US9797889B2 (en) 2017-10-24
JP2020097597A (ja) 2020-06-25
PT3783011T (pt) 2022-10-26
AU2020213288B2 (en) 2022-07-07
AU2014236949A1 (en) 2015-09-24
EP3783011A1 (en) 2021-02-24
CN105143249A (zh) 2015-12-09
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
BR112015023394B1 (pt) 2023-08-29
KR20210036422A (ko) 2021-04-02
SG10201601929YA (en) 2016-04-28
AU2014236949B2 (en) 2018-08-02
IL240985B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
JP7843318B2 (ja) 構造的相補性による生物発光の活性化

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210325

Application number text: 1020157024687

Filing date: 20150909

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210423

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211110

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211110

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220210

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210621

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210423

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220927

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230223

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221125

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220927

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220915

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220615

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220210

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211110

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210621

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210423

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230524

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230223

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101001130

Request date: 20230524

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101001130; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230524

Effective date: 20240322

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240322

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230524

Decision date: 20240322

Appeal identifier: 2023101001130

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20240327

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20240322

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240612

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration